177 related articles for article (PubMed ID: 37509605)
1. The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo.
Mitobe Y; Suzuki S; Nakagawa-Saito Y; Togashi K; Sugai A; Sonoda Y; Kitanaka C; Okada M
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509605
[TBL] [Abstract][Full Text] [Related]
2. Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells.
Mitobe Y; Suzuki S; Nakagawa-Saito Y; Togashi K; Sugai A; Sonoda Y; Kitanaka C; Okada M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686602
[TBL] [Abstract][Full Text] [Related]
3. CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells.
Mitobe Y; Nakagawa-Saito Y; Togashi K; Suzuki S; Sugai A; Matsuda KI; Sonoda Y; Kitanaka C; Okada M
Anticancer Res; 2022 Oct; 42(10):4727-4733. PubMed ID: 36192008
[TBL] [Abstract][Full Text] [Related]
4. CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells.
Togashi K; Suzuki S; Mitobe Y; Nakagawa-Saito Y; Sugai A; Takenouchi S; Sugimoto M; Kitanaka C; Okada M
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201546
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
6. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
7. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
8. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
9. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.
Danovi D; Meulmeester E; Pasini D; Migliorini D; Capra M; Frenk R; de Graaf P; Francoz S; Gasparini P; Gobbi A; Helin K; Pelicci PG; Jochemsen AG; Marine JC
Mol Cell Biol; 2004 Jul; 24(13):5835-43. PubMed ID: 15199139
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway.
Togashi K; Okada M; Suzuki S; Sanomachi T; Seino S; Yamamoto M; Yamashita H; Kitanaka C
Anticancer Res; 2020 Sep; 40(9):4961-4968. PubMed ID: 32878784
[TBL] [Abstract][Full Text] [Related]
11. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
12. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
13. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.
Hüllein J; Słabicki M; Rosolowski M; Jethwa A; Habringer S; Tomska K; Kurilov R; Lu J; Scheinost S; Wagener R; Huang Z; Lukas M; Yavorska O; Helfrich H; Scholtysik R; Bonneau K; Tedesco D; Küppers R; Klapper W; Pott C; Stilgenbauer S; Burkhardt B; Löffler M; Trümper LH; Hummel M; Brors B; Zapatka M; Siebert R; Kreuz M; Keller U; Huber W; Zenz T
Cancer Res; 2019 Jun; 79(12):3125-3138. PubMed ID: 31000522
[TBL] [Abstract][Full Text] [Related]
14. Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.
Lama R; Xu C; Galster SL; Querol-García J; Portwood S; Mavis CK; Ruiz FM; Martin D; Wu J; Giorgi MC; Bargonetti J; Wang ES; Hernandez-Ilizaliturri FJ; Koudelka GB; Chemler SR; Muñoz IG; Wang X
Front Oncol; 2022; 12():933446. PubMed ID: 35992795
[TBL] [Abstract][Full Text] [Related]
15. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
16. Dual Targeting of MDM4 and FTH1 by MMRi71 for Induced Protein Degradation and p53-Independent Apoptosis in Leukemia Cells.
Lama R; Galster SL; Xu C; Davison LW; Chemler SR; Wang X
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431769
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
18. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
[TBL] [Abstract][Full Text] [Related]
19. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
Espadinha M; Lopes EA; Marques V; Amaral JD; Dos Santos DJVA; Mori M; Daniele S; Piccarducci R; Zappelli E; Martini C; Rodrigues CMP; Santos MMM
Eur J Med Chem; 2022 Nov; 241():114637. PubMed ID: 35961068
[TBL] [Abstract][Full Text] [Related]
20. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
